| Biological |
| AAV Gene Therapy Core | Dr. Bing Wang |
| The goal of the VMI AAV core is to provide a novel platform for faculties in the VMI to win research grants and develop new molecular therapeutic technique from Bench to Bedside. We are actively working collaboratively with scientists and clinicians in the VMI and across the Department of Medicine.
As a partner, the Core is open to all investigators at Pitt for grant applications Location: Oakland, BST |
| Cancer Pharmacokinetics and Pharmacodynamics Facility, UPMC Hillman Cancer Center | Robert Parise, PhD |
| The UPMC Hillman Cancer Center Cancer Pharmacokinetics and Pharmacodynamics Facility provides accessible, economical, comprehensive, and state-of-the-art bioanalytical, pharmacokinetic and pharmacology research services that support preclinical and clinical research programs focused on oncology at UPMC Hillman Cancer Center and medical institutions nationwide. Resources include HPLC-UV/fluorescence, ICP-MS, LC-MS/MS, LSC, ELISA, and in vivo rodent procedures, as well as advanced PK software suites and expertise for preclinical and clinical projects. Location: Shadyside, HCC |
| Genome Editing, Transgenic & Virus Core | Jen Orwig |
| MWRI’s Genome Editing, Transgenic, and Virus (GETV) Core Facility provides leadership, technical expertise, advice, and training for investigators both within and outside the University of Pittsburgh community. The core is comprised of three functional sections:
1) Molecular cloning (plasmid, virus, CRISPR/Cas9)
2) Viral vectors (lentivirus, adenovirus, adeno-associated virus)
3) Animal services (transgenic, knockout, cryopreservation, re-derivation, and more) Location: Oakland, MWRI |
| Immunologic Monitoring and Cellular Products Laboratory | General email |
| IMCPL provides end-to-end CMC development and manufacturing support for cell and gene therapy (CGT) programs across transplantation, oncology, autoimmune diseases, and rare disorders. Its core strength is managing the CMC lifecycle, from process and analytical development through GMP manufacturing, process characterization, regulatory strategy, and clinical-stage support. IMCPL integrates scientific, manufacturing, quality, and regulatory expertise to establish robust, scalable, and compliant processes. This integrated CMC approach helps sponsors advance CGT products efficiently from development through clinical translation.
Location: Riverside, RVERA |
| Innovative Technologies Development Core | Sebastien Gingras |
| The Innovative Technologies Development Core provides expert design and implementation of gene targeting strategies using various methods, including CRISPR-Cas9, in mice and cells. Location: Shadyside, FORD |
| Pitt BioRepository Database | PBD administrators |
| The Pitt BioRepository Database is a searchable database of biorepositories at the University of Pittsburgh. Relevant information regarding purpose of the study and type and numbers of samples contained help interested investigators find what they need. Principal investigator contact information is provided to facilitate collaboration. Location: Online |
| Positron Emission Tomography (PET) Research Center | James Ruszkiewicz |
| The Positron Emission Tomography (PET) Research Center provides PET imaging resources for clinical research and pre-clinical studies. Radiotracer production and development are also available. The PET Center imaging data analysis team offers biostatistics, bioinformatics, and data management for imaging data. Location: Oakland, PRESBY |
| Small Animal Multimodal Imaging and Radiotherapeutic Applications Facility (SaMIRA), Hillman Cancer Center | Jessie Nedrow |
| SaMIRA, formerly the IVIF, provides state-of-the-art multimodal imaging and specialized support for the development and evaluation of radiopharmaceuticals across UPMC Hillman Cancer Center programs. Its facility offers a full suite of advanced small animal imaging platforms, including PETCT, SPECTCT (coming 2026), optical imaging (bioluminescence and fluorescence), MRI, and ultrasound; enabling real time, noninvasive assessment of disease biology and therapeutic response in preclinical models. These capabilities help refine experimental design, reduce animal use, and promote ethical, reproducible research.
In addition to imaging services, SaMIRA supports radiopharmaceutical innovation by leveraging inhouse expertise in PET and SPECT tracer development, radiotherapeutic design and testing, and access to dedicated radiochemistry laboratories and radiation approved facilities. SaMIRA also contributes to clinical research by processing and evaluating patient samples from radiopharmaceutical trials. Location: Shadyside, HCC |
| Chemical |
| Cancer Pharmacokinetics and Pharmacodynamics Facility, UPMC Hillman Cancer Center | Robert Parise, PhD |
| The UPMC Hillman Cancer Center Cancer Pharmacokinetics and Pharmacodynamics Facility provides accessible, economical, comprehensive, and state-of-the-art bioanalytical, pharmacokinetic and pharmacology research services that support preclinical and clinical research programs focused on oncology at UPMC Hillman Cancer Center and medical institutions nationwide. Resources include HPLC-UV/fluorescence, ICP-MS, LC-MS/MS, LSC, ELISA, and in vivo rodent procedures, as well as advanced PK software suites and expertise for preclinical and clinical projects. Location: Shadyside, HCC |
| Peptide and Peptoid Synthesis Facility | Kazi Islam |
| The Peptide and Peptoid Synthesis Core provides comprehensive services for peptide & peptoid synthesis, custom modifications, purification, and characterization to research programs at the University of Pittsburgh and UPMC. Location: Riverside CNBIO |
| Small Animal Multimodal Imaging and Radiotherapeutic Applications Facility (SaMIRA), Hillman Cancer Center | Jessie Nedrow |
| SaMIRA, formerly the IVIF, provides state-of-the-art multimodal imaging and specialized support for the development and evaluation of radiopharmaceuticals across UPMC Hillman Cancer Center programs. Its facility offers a full suite of advanced small animal imaging platforms, including PETCT, SPECTCT (coming 2026), optical imaging (bioluminescence and fluorescence), MRI, and ultrasound; enabling real time, noninvasive assessment of disease biology and therapeutic response in preclinical models. These capabilities help refine experimental design, reduce animal use, and promote ethical, reproducible research.
In addition to imaging services, SaMIRA supports radiopharmaceutical innovation by leveraging inhouse expertise in PET and SPECT tracer development, radiotherapeutic design and testing, and access to dedicated radiochemistry laboratories and radiation approved facilities. SaMIRA also contributes to clinical research by processing and evaluating patient samples from radiopharmaceutical trials. Location: Shadyside, HCC |
|